In March 2015, the US Food and Drug Administration (FDA) approved Actavis’ asenapine (Saphris) for the acute treatment of manic or mixed episodes associated with bipolar disorder in kids between 10 and 17 years.
What steps should clinicians take if psychopharmacologic treatments and school behavioral strategies are insufficient for managing a child with ADHD? We've all been there. ADHD,...